You are here

  • Home
  • Archive
  • Volume 72, Issue 1
  • Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

Citation Tools

Article menu
Clinical and epidemiological research
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Dougados M, Kissel K, Sheeran T, et al
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Annals of the Rheumatic Diseases 2013;72:43-50.